Kurt Gustafson Biography and Net Worth

CFO of OmniAb

Kurt Gustafson has served as OmniAb’s Executive Vice President, Finance and Chief Financial Officer since March of 2022. Prior to joining OmniAb, Mr. Gustafson served as Executive Vice President and Chief Financial Officer of Spectrum Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, a position he held since 2013. Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly traded biopharmaceutical company, where he was responsible for finance, information technology, facilities, and human resources. Before joining Halozyme in 2009, Mr. Gustafson worked at Amgen Inc. for over 18 years, ultimately serving there as Vice President, Finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as Treasurer, Vice President, Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson is currently a member of the Board of Directors of Xencor, Inc., a clinical stage biopharmaceutical company. Mr. Gustafson received a BA in Accounting at North Park University and an MBA from the University of California, Los Angeles.

What is Kurt A. Gustafson's net worth?: The estimated net worth of Kurt A. Gustafson is at least $370.00 thousand as of April 7th, 2026. Gustafson owns 261,483 shares of OmniAb stock worth more than $369,998 as of May 7th. This net worth evaluation does not reflect any other investments that Gustafson may own. Learn More about Kurt A. Gustafson's net worth.
How do I contact Kurt A. Gustafson?: The corporate mailing address for Gustafson and other OmniAb executives is 65 EAST 55TH STREET 18TH FLOOR, NEW YORK NY, 10022. OmniAb can also be reached via phone at 510-250-7800 and via email at [email protected]. Learn More on Kurt A. Gustafson's contact information.
Has Kurt A. Gustafson been buying or selling shares of OmniAb?: Over the course of the past ninety days, Kurt A. Gustafson has sold $10,300.37 of OmniAb stock. Most recently, Kurt A. Gustafson sold 6,913 shares of the business's stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $1.49, for a transaction totalling $10,300.37. Following the completion of the sale, the chief financial officer now directly owns 261,483 shares of the company's stock, valued at $389,609.67. Learn More on Kurt A. Gustafson's trading history.
Who are OmniAb's active insiders?: OmniAb's insider roster includes Charles Berkman (Insider), Matthew Foehr (President and CEO), Kurt Gustafson (CFO), John Higgins (Director), and Steven Love (Director). Learn More on OmniAb's active insiders.
Are insiders buying or selling shares of OmniAb?: In the last year, OmniAb insiders bought shares 4 times. They purchased a total of 167,261 shares worth more than $237,806.87. In the last year, insiders at the sold shares 12 times. They sold a total of 163,335 shares worth more than $283,036.05. The most recent insider tranaction occured on April, 7th when CEO Matthew W Foehr sold 19,244 shares worth more than $28,673.56. Insiders at OmniAb own 8.6% of the company. Learn More about insider trades at OmniAb.
Information on this page was last updated on 4/7/2026.

Kurt A. Gustafson Insider Trading History at OmniAb

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/7/2026	Sell	6,913	$1.49	$10,300.37	261,483
2/18/2026	Sell	9,301	$1.71	$15,904.71	268,851
2/17/2026	Sell	6,828	$1.70	$11,607.60	259,402
12/8/2025	Sell	23,922	$1.96	$46,887.12	252,688
4/1/2025	Sell	11,963	$2.37	$28,352.31	217,492
2/19/2025	Sell	7,255	$3.67	$26,625.85	206,211
1/21/2025	Sell	15,526	$3.24	$50,304.24	212,720
4/8/2024	Sell	6,954	$5.27	$36,647.58	176,697
4/1/2024	Sell	11,849	$5.46	$64,695.54	170,110
11/28/2022	Buy	10,000	$2.81	$28,100.00	170,062

Kurt A. Gustafson Buying and Selling Activity at OmniAb

OmniAb Company Overview

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Today's Range

Now: $1.42

$1.42

$1.44

50 Day Range

MA: $1.64

$1.36

$2.00

2 Week Range

Now: $1.42

$1.22

$2.30

Volume

53,732 shs

Average Volume

398,656 shs

Market Capitalization

$204.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.07